Relmada Therapeutics (RLMD) HAP Data Significantly Improves Commercial Outlook - Analyst

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Relmada Therapeutics (RLMD) HAP Data Significantly Improves Commercial Outlook - Analyst

Relmada Therapeutics Inc (RLMD) PT Raised to $90 at Truist Securities

July 27, 2021 10:14 AM EDT

Truist Securities analyst Joon Lee raised the price target on Relmada Therapeutics Inc (NASDAQ: RLMD) to $90.00 (from $75.00) while maintaining a Buy rating.

... More

Relmada Therapeutics (RLMD) to Resume Trading at 8:30 a.m.

July 27, 2021 8:26 AM EDT

Relmada Therapeutics (NASDAQ: RLMD) to Resume Trading at 8:30 a.m.

... More

Relmada Therapeutics (RLMD) Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential

July 27, 2021 7:35 AM EDT

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today top-line results of the human abuse potential (HAP) study with REL-1017, a novel NMDA receptor (NMDAR) channel blocker and the company's lead candidate in Phase 3... More

Relmada Therapeutics (RLMD) Halted, News Pending

July 27, 2021 7:25 AM EDT

Relmada Therapeutics (NASDAQ: RLMD) Halted, News Pending

... More